Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470550 | 0.76 | MAPT (0.34) | GAAMAPTHPGDHTTCRHBP | |
| SCHEMBL2565825 | 0.75 | GAA (0.35) | GAAMAPTHPGDSMN1; SMN2POLB | |
| SCHEMBL3487176 | 0.73 | ALDH1A1 (0.39) | GAAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL27675643 | 0.72 | ALDH1A1 (0.40) | GAAMAPTHPGDCRHBPCRHR2 | |
| SCHEMBL20517661 | 0.71 | ALDH1A1 (0.43) | GAAMAPTHTTALDH1A1MEN1 | |
| SCHEMBL17915374 | 0.70 | MAPT (0.45) | MAPTSMN1; SMN2ALDH1A1POLBMEN1 | |
| SCHEMBL26162639 | 0.67 | ALDH1A1 (0.35) | GAAMAPTHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL26162776 | 0.67 | POLB (0.34) | GAAMAPTHPGDHTTALDH1A1 | |
| SCHEMBL2298371 | 0.67 | ATM (0.41) | GAAMAPTHPGDHTTSMN1; SMN2 | |
| SCHEMBL25345518 | 0.66 | ALDH1A1 (0.39) | GAAMAPTHPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443115-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | GAA 23/4885MAPT 719/4885HPGD 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.